Reason for request

Re-assesement of the actual benefit at the request of the Committee (pursuant to Article R 163-21 of the French Social Security Code) - Extensions of indication: Diagnosis of liver lesions: diagnosis of the spread of malignant lesions, whether hepatic or not, by selective hepatic arterial injection. Embolisation with surgical glues: in association with surgical glues during vascular embolisations.

-


Clinical Benefit

Substantial

Interventional radiology
The actual benefit of LIPIODOL is substantial.

The Committee recommends inclusion on the list of medicines approved for hospital use in the indications of interventional radiology and liver lesion diagnosis and recommendscontinued inclusion for lymphography on the list of medicinal products approved for hospital use.

Low

Lymphography
the actual benefit of LIPIODOL is low.

Diagnosis of liver lesions
the actual benefit of LIPIODOL is low.


Clinical Added Value

no clinical added value

LIPIODOL ULTRA-FLUIDE 480 mg/ml, solution for injection does not provide any improvement in actual benefit (IAB V, non-existent) compared with existing alternatives in the diagnosis of liver lesions and vascular embolisation.